Clinical Development

Clinical Pipeline

KINASE INHIBITION

Sorafenib

Liver Cancer

Unresectable

Kidney Cancer

Advanced

Thyroid Cancer

Differentiated, DECISION – Monotherapy

PROTEASOME INHIBITION

Carfilzomib

Multiple Myeloma

Advanced myeloma, monotherapy
ASPIRE – Relapsed, +/- lenalidomide/dexamethasone
ENDEAVOR-Relapsed, vs. bortezomib + dexamethasone
CLARION - Front-line, vs. bortezomib + melphalan + prednisone

Oprozomib

Hematologic Malignancies

Monotherapy - Waldenstroms and myeloma
Oprozomib + melphalan + prednisone - in newly diagnosed, transplant ineligible
Oprozomib + pomalidomide + dexamethasone
Oprozomib + dexamethasone - relapsed/refractory myeloma
Oprozomib + dexamethasone with lenalidomide or cyclophosphamide in newly diagnosed myeloma

Other Cancers

Monotherapy - Advanced Malignancies

Palbociclib 2

Advanced breast cancer
1 Best available care
2 Palbociclib is a Pfizer compound being developed by Pfizer. If approved, Onyx will receive an 8% royalty on  global net sales.